Shopping Cart
- Remove All
- Your shopping cart is currently empty
Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment of the hepatitis B virus and human immunodeficiency virus infection.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $4,600 | 6-8 weeks | |
50 mg | $5,980 | 6-8 weeks | |
100 mg | $7,180 | 6-8 weeks | |
1 mL x 10 mM (in DMSO) | $2,700 | 6-8 weeks |
Description | Selgantolimod is an effective and selective toll-like receptor 8 agonists for the treatment of the hepatitis B virus and human immunodeficiency virus infection. |
In vitro | Selgantolimod induces the cellular immune mediators interleukin (IL)-12 and IL-8, as well as the antiviral cytokines tumor necrosis factor-α and interferon-γ in vitro in human peripheral blood mononuclear cells. These cytokines reduce HBV DNA, RNA, and antigen levels in HBV-infected primary human hepatocytes. Selgantolimod activates natural killer and mucosal-associated invariant T cells, stimulates cluster of differentiation (CD)-8+ T-cell proliferation, and increases IFNγ production while lowering programmed cell death protein 1 expression by HBV-specific CD8+-T cells in vitro in peripheral blood mononuclear cells [1]. |
In vivo | Selgantolimod (p.o., once-weekly) treatment induces dose-dependent increases in serum IL-12 and IL-1 receptor antagonist (IL-1RA) in cynomolgus monkeys and causes functional cure in the woodchuck model of chronic HBV [1]. |
Alias | GS-9688 |
Molecular Weight | 293.34 |
Formula | C14H20FN5O |
Cas No. | 2004677-13-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.